Zydus Lifesciences Q1 FY27 Net Profit at ₹939.8 Crore, EPS ₹9.35
Zydus Lifesciences reported Q1 FY27 consolidated net profit of ₹939.8 crore, down from ₹1,466.8 crore in the prior year quarter. Total income from operations rose to ₹8,017 crore. EPS was ₹9.35. The results were published on August 12, 2026.
The decrease in net profit compared to the previous year's quarter might be a point of concern for investors. However, the increase in revenue and the routine nature of quarterly results publication suggest a moderate impact.
The net profit has decreased compared to the same quarter last year, but the income from operations has increased. The company has published its results as per regulations, without any significant positive or negative commentary beyond the figures themselves.
Zydus Lifesciences Limited has published its unaudited financial results for the quarter ended June 30, 2026. The company reported a total income from operations of ₹80,170 million (₹8,017 crore) for the quarter. The net profit after tax and non-controlling interest stood at ₹9,398 million (₹939.8 crore). The earnings per share (EPS) for the quarter was ₹9.35 on a basic and diluted basis.
These results are an extract of the detailed format filed with the stock exchanges. The full financial results and limited review reports are available on the company's website (www.zyduslife.com), BSE (www.bseindia.com), and NSE (www.nseindia.com).
The newspaper publication regarding these unaudited financial results for the quarter ended June 30, 2026, appeared in the Financial Express on August 12, 2026.
What to do with a filing like this
Zydus Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zydus Lifesciences Limited. Read the original for the full detail.